Editorial

In 2009, the journal “Inflammation & Allergy - Drug Targets” starts to publish the 8th volume. Reading the names of excellent and well-recognized scientists - either serving as Regional Editors or being placed as members of the Editorial Advisory Board - it was a pleasure to accept the offer by Bentham Science Publishers Ltd., to overtake for a limited period the position of an Editor-in-Chief. The rapid and continuous upsurge of interesting data from basic, translational and clinical research in the subject of inflammation and allergy, together with visions for novel therapeutic strategies necessitates the publication of this journal. The worldwide contributions at the state-of-the-art science to this journal should furnish the updated and latest news to the researchers, the clinicians and, also to the students, because they have once to succeed into the footstep of all of us. We should ignite a fire of continued interest in all of them by offering a highly ranked platform of rapid communication and nondogmatic discussion. Concepts, methodologies and therapies are ever changing and progress in the areas of inflammation and allergy promises to offer breakthrough in the future in cancer, diabetes, neurological disorders, heart and vascular disease and many other diseases, still in an orphan status in respect to be understood at a molecular level or lacking therapeutic options. Of course, everybody of us experiences during the daily work that publications in science arise tsunami-like, and many of them are disappearing soon after the release of a first couple of volumes. This must not be the case with “Inflammation & Allergy - Drug Targets”. All of us, the members of the Editorial Advisory Board, the Regional Editors and the EiC can help with their networks that this journal growths academically, stays open-minded and is totally devoted to search for non-dogmatic truth in medical science - for the sake of patients; everybody of us can be and will be tomorrow a patient.